AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04607421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
Study NCT04607421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
Study NCT04607421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
Study NCT04607421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
Study NCT04607421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 150 mg or 500 mg Tablet
Study NCT04607421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
Study NCT03506594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency non ablative
Description: The application of RF was performed by physical therapist trained in the technique of radiofrequency through the CAPENERGY device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41°C radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
Study NCT04042415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Patients will be treated with a diet regimen of mild caloric restriction (15-20% caloric restriction)
Study NCT04042415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric restriction without cow's milk and gluten
Description: Patients will be treated with mild caloric restriction (15-20% caloric restriction) plus excluding from diet cow's milk, its derivatives and gluten.
Study NCT03068026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaBreath
Description: The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
Study NCT02920567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
Study NCT00194675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: Dutasteride 0.5 mg orally daily
Study NCT03068026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed Lip Breathing technique
Description: Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
Study NCT01516450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1550188 IV
Description: Single IV dose of belimumab 200 mg
Study NCT00194675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel 7.5 g daily topical
Study NCT00194675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo dutasteride
Description: placebo dutasteride orally daily
Study NCT05072327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mohs surgery
Description: Mohs surgery of eyelid
Study NCT05072327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mohs surgery
Description: Mohs surgery of eyelid
Study NCT01516450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1550188 SC
Description: Single SC dose of belimumab 200mg
Study NCT01819961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCT/LCT and fish oil
Study NCT01819961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCT/LCT
Study NCT03630068 — intervention group
Intervention type: PROCEDURE
Intervention: Stereotactic percutaneous image-guided microwave ablation
Description: Stereotactic percutaneous image-guided microwave ablation implies the use of computer-assisted navigation technology for 3D trajectory planning and stereotactic placement of ablation probes, before applying local microwave ablation therapy
Study NCT01582724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-care acupressure at three predefined points
Description: Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
Study NCT01056523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
Study NCT01056523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine arabinoside
Description: Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
Study NCT01954628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125
Description: Synthetic SHIP1 activator
Study NCT01954628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT00389077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine 50 mg tablets
Study NCT05072327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy of eyelid
Study NCT01076075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
Study NCT03656640 — intervention group
Intervention type: DRUG
Intervention: Gammanorm
Description: Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
Study NCT01823653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liposonix System (Model 2)
Description: Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
Study NCT01520922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
Study NCT01520922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
Study NCT01076075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo to pioglitazone
Description: Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
Study NCT01076075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo to Sitagliptin
Description: Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
Study NCT01076075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pioglitazone
Description: Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
Study NCT01076075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride or gliclazide
Description: Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
Study NCT01076075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride or gliclazide
Description: Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
Study NCT01076075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin
Study NCT01076075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin
Study NCT02185170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-urethral resection
Description: All subjects of the study are going to have a trans-urethral resection of prostate.
Study NCT02185170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the FEMTO-ST institute medical device
Description: The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
Study NCT02185170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the Light-CT scanner
Description: The Light-CT Scanner is use in the tissue structural observation
Study NCT02920567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
Study NCT04046952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Statseal with TR Band
Description: Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
Study NCT04046952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TR band only
Description: Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
Study NCT01401075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mistletoe extract
Description: subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
Study NCT01401075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxifluridine
Description: 600 - 900 mg per day orally, depending on weight and status of the patient
Study NCT01401075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxifluridine
Description: 600 - 900 mg per day orally, depending on weight and status of the patient
Study NCT01076075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone rescue therapy
Description: Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
Study NCT01076075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone rescue therapy
Description: Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
Study NCT02116478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical proximal medial gastrocnemius recession
Description: proximal medial gastrocnemius recession
Study NCT04971330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access HCV
Description: All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status
Study NCT03114059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glaucoma diagnostics
Description: Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
Study NCT04610164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Prior to surgery, the patient will receive 1 gram of IV TXA
Study NCT04932070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
Study NCT02663583 — intervention group
Intervention type: BEHAVIORAL
Intervention: Symptom Questionnaires
Description: Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.
Study NCT02663583 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dysphagia Inventory Questionnaire
Description: Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.
Study NCT02663583 — intervention group
Intervention type: BEHAVIORAL
Intervention: Activity Bands
Description: Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.
Study NCT02909803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lentil Variety
Description: Participants will consume 8 varieties of lentils that are cooked by boiling
Study NCT02909803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Bread
Description: Participants will consume white bread on at least two different test days
Study NCT01522586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP09031
Description: DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
Study NCT01522586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
Study NCT01872234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two-lead CRT-P
Description: The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
Study NCT04498494 — intervention group
Intervention type: DEVICE
Intervention: ECG
Description: 12-lead ECG
Study NCT02385136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT02704910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Subthalamic stimulation
Description: Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
Study NCT02704910 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Subthalamic stimulation
Description: Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
Study NCT03810404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate supplementation
Description: Interventions:~The experimental procedure for each athlete included an acute SB supplementation in a different-dose regimen in order to assess whether the dose affects the actual physical and exercise capacity (doses: 0.15-, 0.25-, 0.35- and 0.50 g/kgFFM (0.12-, 0.20-, 0.28- and 0.40 g/kgBM), respectively). SB (Alkala, SANUM, Poland) will be administered as dissolved form in a 750 ml of fluid (water + fruit juice). On testing days the SB will be taken before physical and exercise capacity tests session.~Between the SB and PLA or a PLA and SB treatments, a minimum 7-day washout period will be introduced.
Study NCT03810404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Interventions:~The experimental procedure for each athlete will be included an PLA supplementation. Placebo will be administered in a form of 750 ml of fluid (water + fruit juice). On testing days the PLA will be taken before physical and exercise capacity tests session.~Between the PLA and SB or a SB and PLA treatments, a minimum 7-day washout period will be introduced.
Study NCT04485429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 0.5 mg/kg every 12 hours intravenously for the first 14 days; followed by 0.5 mg/kg/day from day 15 to day 21; followed by 0.25mg/kg/day from day 22 to day 25; followed by 0.125 mg/kg/day, from day 26 to day 28 of treatment.
Study NCT04485429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.
Study NCT00468039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin + metformin
Study NCT03231982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group I
Description: Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
Study NCT03231982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group II
Description: Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
Study NCT03455049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Andrographis Paniculata Ext
Description: Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
Study NCT03455049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Andrographis Paniculata Ext
Description: Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
Study NCT06526754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-Printed Liver Model
Description: Participants in the 3D Printed Model Group (3DP) will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. These models will be used to guide the surgical procedures.
Study NCT06526754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Simulation-Based Surgical Planning
Description: Participants in the 3D Virtual Model Group (3DV) will receive surgical planning based on digital simulations using the fastest AI-assisted segmentation method with manual adjustments from Phase Two. These digital simulations will be used to guide the surgical procedures.
Study NCT01616082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Diet (LCD)
Description: A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.
Study NCT01616082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Description: Individuals not on track to achieve their target weight by four weeks received the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects were given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~* Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~* Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated.